Description

Background Mutations in LRRK2, the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson’s disease
(PD). The International LRRK2 Consortium was established to answer three key clinical questions: can LRRK2-associated
PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specifi c
cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2?